Skip to main content

Table 3 Incidence rates (per 1,000 patients-day) of resistant bacteria

From: Ciprofloxacin prophylaxis in high risk neutropenic patients: effects on outcomes, antimicrobial therapy and resistance

 

Period 1 (2005)

Period 2 (2006–2008)

pvalue

Cohort patients

Bacteremia due to Cip-R organisms*

3.02

6.77

0.03

Cip-R enterobacteria

0.38

2.12

0.06

Cip-R Pseudomonas aeruginosa

0.38

0.63

0.71

ESBL production

0.38

1.27

0.26

Cip-R Staphylococcus aureus

0

0.63

0.26

Cip-R CONS

2.27

2.75

0.72

Non-cohort patients in the hematology unit

Cip-R enterobacteria

0.53

2.54

0.004

Cip-R Pseudomonas aeruginosa

0.70

0.32

0.39

ESBL production

0.52

1.59

0.08

Cip-R Staphylococcus aureus

0

0.16

0.52

Cip-R CONS

2.64

2.23

0.65

Hospital

Cip-R enterobacteria

0.76

0.64

0.15

Cip-R Pseudomonas aeruginosa

0.22

0.21

0.78

ESBL production

0.56

0.53

0.74

Cip-R Staphylococcus aureus

0.33

0.23

0.06

Cip-R CONS

0.68

0.60

0.33

  1. Cip-R = ciprofloxacin-resistant; ESBL = extended spectrum beta-lactamase; CONS = coagulase-negative staphylococci; *Total number of bacteremia due to quinolone-resistant organisms available in the cohort only.